Valued at a market cap of $9.3 billion, Alexandria Real Estate Equities, Inc. (ARE) is a leading life science REIT and specializes in collaborative Megacampus ecosystems in major U.S. life science and technology hubs. As of June 30, 2026, the company had a 36 million RSF of operating properties, and 2.8 million RSF of Class A/A+ properties under construction.
Companies valued less than $10 billion are generally classified as “mid-cap” stocks, and Alexandria Real Estate Equities fits this criterion perfectly. Through its high-quality real estate portfolio and venture capital platform, Alexandria supports innovative life science companies while targeting strong occupancy, rental income, returns, and long-term asset value.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
Shares of the Pasadena, California-based company have declined 36.7% from its 52-week high of $88.24. Over the past three months, its shares have increased 13.7%, outpacing the broader State Street Real Estate Select Sector SPDR ETF's (XLRE) 2.3% drop during the same period.
www.barchart.com ARE stock is up 14.3% on a YTD basis, exceeding XLRE's 6.4% return. However, shares of the REIT have dipped 34.3% over the past 52 weeks, lagging behind XLRE's 2.2% rise over the same time frame.
Despite a few fluctuations, the stock has been trading below its 50-day moving average since last year.
www.barchart.com Despite reporting better-than-expected Q2 2026 adjusted FFO of $1.73 per share on Aug. 3, ARE shares tumbled 7.8% the next day as revenue fell 13% year-over-year to $662.78 million and rental income declined to $643.21 million. The 2026 adjusted FFO outlook was narrowed to $6.35 per share - $6.45 per share, with the $6.40 midpoint only modestly above the consensus.
Investors also focused on weaker near-term expectations, with Q4 adjusted FFO expected at the low end of $1.40 per share - $1.50 per share, while the roughly six-week delay in projected dispositions and capital transactions from August to September added uncertainty around the timing of expected cash proceeds.
In comparison, rival Welltower Inc. (WELL) has outperformed ARE stock. WELL stock has increased 25.7% on a YTD basis and 40.6% over the past 52 weeks, lagging behind EXR stock.
Due to the stock’s underperformance over the past year, analysts remain cautious about its prospects. ARE stock has a consensus rating of “Hold” from 17 analysts in coverage, and as of writing, it is trading above the mean price target of $53.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
Worker Tensions in Taiwan Are Rising at Micron. What This Means for MU Stock. Wall Street May Have Overpriced the Fed Rate Hike’s Impact on Citigroup Stock Spreads Broadcom CEO Hock Tan Says He Isn’t Worried – ‘No, Not in the Least’ – About AVGO as AI Extinction Fears Rattle Stocks I Sold Micron Before Q2 Earnings and It Fell 23%. Here’s Why I'm Buying Before the Next Report.